Compounds > febuxostat
Page last updated: 2024-09-04

febuxostat and Proteinuria

febuxostat has been researched along with Proteinuria in 5 studies

Research

Studies (5)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's3 (60.00)24.3611
2020's2 (40.00)2.80

Authors

AuthorsStudies
Hosoya, T; Iwasa, N; Kataoka, H; Kimura, K; Mochizuki, T; Nitta, K; Ohara, M; Tsuchiya, K; Tsuruta, Y; Yoshida, R1
Chin-Kanasaki, M; Imamura-Uehara, Y; Kato, K; Kume, S; Kuwagata, S; Maegawa, H; Nakagawa, Y; Ohno, S; Takeda, N; Yamahara, K; Yasuda-Yamahara, M1
Hosoya, T; Kimura, K; Ohno, I; Shibagaki, Y1
Fahmi, AN; Salem, HA; Shebl, AM; Shehatou, GS1
Hoshi, H; Kazama, JJ; Terawaki, H1

Trials

1 trial(s) available for febuxostat and Proteinuria

ArticleYear
Urate-lowering therapy for CKD patients with asymptomatic hyperuricemia without proteinuria elucidated by attribute-based research in the FEATHER Study.
    Scientific reports, 2022, 03-08, Volume: 12, Issue:1

    Topics: Creatinine; Febuxostat; Female; Gout Suppressants; Humans; Hyperuricemia; Male; Proteinuria; Renal Insufficiency, Chronic; Treatment Outcome; Uric Acid

2022

Other Studies

4 other study(ies) available for febuxostat and Proteinuria

ArticleYear
Improvement in Decline Rate of Estimated Glomerular Filtration Rate after Febuxostat Treatment in a Fabry Disease Patient with Enzyme Replacement Therapy-resistant Proteinuria.
    Internal medicine (Tokyo, Japan), 2022, Oct-15, Volume: 61, Issue:20

    Topics: Adult; alpha-Galactosidase; Enzyme Replacement Therapy; Fabry Disease; Febuxostat; Glomerular Filtration Rate; Humans; Hyperuricemia; Proteinuria; Treatment Outcome; Uric Acid

2022
Safety, efficacy and renal effect of febuxostat in patients with moderate-to-severe kidney dysfunction.
    Hypertension research : official journal of the Japanese Society of Hypertension, 2014, Volume: 37, Issue:10

    Topics: Aged; Blood Pressure; Dose-Response Relationship, Drug; Endpoint Determination; Febuxostat; Female; Glomerular Filtration Rate; Gout Suppressants; Humans; Male; Middle Aged; Prospective Studies; Proteinuria; Renal Insufficiency, Chronic; Thiazoles; Uric Acid

2014
Febuxostat exerts dose-dependent renoprotection in rats with cisplatin-induced acute renal injury.
    Naunyn-Schmiedeberg's archives of pharmacology, 2016, Volume: 389, Issue:8

    Topics: Acute Kidney Injury; Animals; Anti-Inflammatory Agents; Antioxidants; Biomarkers; Cisplatin; Creatinine; Cytoprotection; Disease Models, Animal; Dose-Response Relationship, Drug; Enzyme Inhibitors; Febuxostat; Glutathione; Inflammation Mediators; Kidney; L-Lactate Dehydrogenase; Male; Malondialdehyde; Nitric Oxide; Oxidative Stress; Proteinuria; Rats, Sprague-Dawley; Serum Albumin; Superoxide Dismutase; Tumor Necrosis Factor-alpha; Urological Agents; Xanthine Oxidase

2016
Effect of switching xanthine oxidoreductase inhibitor from febuxostat to topiroxostat on urinary protein excretion.
    Clinical and experimental nephrology, 2017, Volume: 21, Issue:2

    Topics: Aged; Aged, 80 and over; Drug Substitution; Enzyme Inhibitors; Febuxostat; Female; Gout Suppressants; Humans; Hyperuricemia; Kidney; Male; Middle Aged; Nitriles; Proteinuria; Pyridines; Renal Insufficiency, Chronic; Treatment Outcome; Xanthine Dehydrogenase; Xanthine Oxidase

2017